On Wednesday August 23, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q2 2023 report (which will have been published earlier on August 23, at 07.30 CET).…
Devyser's novel test for detecting donor-derived cell-free DNA in blood samples from kidney-transplant patients and its product for screening and follow-up of stem cell transplanted…
Devyser has inaugurated its CLIA-certified laboratory in Atlanta, Georgia. The laboratory will offer clinical test services for hereditary diseases, oncology, and post-transplant…
Devyser is thrilled to announce the launch of two new products, Devyser LynchFAP and Devyser BRCA PALB2. These kits offer efficient, targeted, and confident analysis of genes associated…
Devyser's Deputy CEO and founder Ulf Klangby will leave his position within the company for an advisory role as a consultant as of July 1, 2023.
Ulf Klangby will leave his operational…
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted regulatory approval in Canada. Devyser already has a contract with Canada’s Héma-Québec to…
“The first quarter of the year saw continued strong growth, record gross margin and the launching of our first IVDR-approved product. After the end of the quarter, we were also able to…
Devyser is today announcing that the company's clinical testing laboratory in Roswell in Atlanta, Georgia, has received CLIA certification. This certification allows the Devyser US lab to…
On Tuesday May 9, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q1 2023 report (which will have been published earlier on May 9, at 07.30 CET). The…
Devyser has been awarded the Swecare Export Award 2023. The prize is awarded to companies that "with creativity, commitment and scope put Swedish innovation in health and healthcare on…
